COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.
Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.
COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.
Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.
Get expert clinical insights, study design support, and statistical analysis.
Explore our collection of clinical research, recent press, podcasts, and more.
Cancer is an insidious disease. Even after surgery or aggressive systemic therapy, malignant cells often take refuge in hard-to-identify places in the body before emerging again to cause recurring illness. For many years, researchers…
The FDA plays an incredibly important role in the process of developing, distributing, and monitoring therapeutic products. So when something changes at the FDA, the entire life sciences community sits up and takes notice….
Real-world data (RWD) from electronic health records (EHRs) is increasingly recognized as a powerful asset for oncology research. It enables stakeholders across industry and academia to evaluate treatment patterns, assess comparative effectiveness, identify safety…
Partner with COTA for the highest-quality curated cancer patient datasets.
